17 completed. 17 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Completed 17 |
| Phase 2 | 4 | Completed 4 |
Follow Conjunctivitis: new trials by email Literature Review of Conjunctivitis trials Research Report on Conjunctivitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects PRO-231, VIGAMOXI® - Ophthalmological Agent Toxicity, Bacterial Conjunctivitis | Phase 1 | Completed | Laboratorios Sophia S.A de C.V. | 37 | 2024-01-30 | 2025-06-15 |
| A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults MDI-1228_mesylate Ophthalmic Solution, Placebo - Allergic Conjunctivitis | Phase 1 | Completed | Shanghai Medinno Pharmaceutical Technology Co., Ltd. | 40 | 2023-10-06 | 2024-07-09 |
| Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease INV-102, Vehicle - Dry Eye Disease | Phase 1 / Phase 2 | Completed | Invirsa, Inc. | 84 | 2022-08-30 | 2026-09-18 |
| Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial Cyclosporine 0.05% eye drops, Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3% - Vernal Keratoconjunctivitis, Cyclosporine 0.05% Eye Drops | Phase 1 | Completed | Second Affiliated Hospital of Nanchang University | 48 | 2020-07-01 | 2022-04-29 |
| Safety and Immunogenicity of a Chlamydia Vaccine CTH522 CTH522-CAF01 IM, CTH522-CAF09b IM, CTH522 ID - Trachoma | Phase 1 | Completed | Statens Serum Institut | 65 | 2020-02-17 | 2024-08-22 |
| A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers PP-001, Placebo - Keratoconjunctivitis, Ocular Surface Disease | Phase 1 | Completed | Panoptes Pharma GmbH | 45 | 2018-11-20 | 2024-01-12 |
| A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution - Conjunctivitis, Allergic | Phase 1 / Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 70 | 2018-10-02 | 2025-02-24 |
| A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution - Allergic Conjunctivitis | Phase 1 / Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 52 | 2018-09-08 | 2025-04-08 |
| A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis AK002 - Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis | Phase 1 | Completed | Allakos Inc. | 30 | 2018-02-26 | 2019-08-29 |
| Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects PRO-174, Sophixín Ofteno® - Conjunctivitis, Conjunctivitis, Bacterial | Phase 1 | Completed | Laboratorios Sophia S.A de C.V. | 30 | 2018-01-25 | 2019-10-25 |
| Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis XmAb7195, Placebo - Allergic Rhinitis, Allergic Conjunctivitis | Phase 1 | Completed | Xencor, Inc. | 72 | 2014-05-01 | 2017-01-24 |
| Safety and Efficacy of PG101 for Dry Eye Syndrome PG101 - Dry Eye Syndrome | Phase 1 / Phase 2 | Completed | Rhodes Pharmaceuticals, L.P. | 72 | 2013-12-01 | 2014-03-05 |
| A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, R348 Ophthalmic Solution, 1.0% - Keratoconjunctivitis Sicca | Phase 1 | Completed | Rigel Pharmaceuticals | 36 | 2012-11-01 | 2014-08-04 |
| Safety and Comfort of AL-4943A Ophthalmic Solution Olopatadine hydrochloride ophthalmic solution, 0.7%, Olopatadine hydrochloride ophthalmic solution vehicle, Ketotifen fumarate ophthalmic solution, 0.025% - Allergic Conjunctivitis | Phase 1 | Completed | Alcon Research | 50 | 2011-04-01 | 2015-03-03 |
| A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS) voclosporin ophthalmic solution - Keratoconjunctivitis Sicca | Phase 1 | Completed | Lux Biosciences, Inc. | 35 | 2009-02-01 | 2012-06-22 |
| Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract 300 IR grass pollen allergen extract tablet, Placebo tablet - Seasonal Allergic Rhinitis | Phase 1 | Completed | Stallergenes Greer | 89 | 2007-09-01 | 2016-05-23 |
| Systemic Pharmacokinetics of BOL-303224-A BOL-303224-A - Conjunctivitis, Bacterial | Phase 1 | Completed | Bausch & Lomb Incorporated | 24 | 2006-10-01 | 2011-12-09 |
Conjunctivitis, Allergic (7) · Keratoconjunctivitis Sicca (4) · Conjunctivitis, Bacterial (3) · Dry Eye Syndromes (2) · Chlamydia Infections (1) · Dermatitis, Atopic (1) · Keratoconjunctivitis (1) · Rhinitis (1) · Rhinitis, Allergic (1) · Rhinitis, Allergic, Seasonal (1) · Trachoma (1)
Conjunctival Diseases (17) · Eye Diseases (17) · Hypersensitivity (8) · Hypersensitivity, Immediate (8) · Immune System Diseases (8) · Corneal Diseases (6) · Infections (5) · Keratitis (5) · Bacterial Infections (4) · Bacterial Infections and Mycoses (4) · Eye Infections (4) · Eye Infections, Bacterial (4) · Keratoconjunctivitis (4) · Lacrimal Apparatus Diseases (4)
AK002 (1) · Cyclosporine (1) · Gels (1) · Loteprednol Etabonate (1) · Moxifloxacin (1) · Olopatadine Hydrochloride (1) · Ophthalmic Solutions (1) · Sodium Chloride (1) · Sublingual Immunotherapy (1) · besifloxacin (1) · ketotifen fumarate ophthalmic solution (1)
Aldeyra Therapeutics, Inc. (2) · Laboratorios Sophia S.A de C.V. (2) · Alcon Research (1) · Allakos Inc. (1) · Bausch & Lomb Incorporated (1) · Invirsa, Inc. (1) · Lux Biosciences, Inc. (1) · Panoptes Pharma GmbH (1) · Rhodes Pharmaceuticals, L.P. (1) · Rigel Pharmaceuticals (1) · Second Affiliated Hospital of Nanchang University (1) · Shanghai Medinno Pharmaceutical Technology Co., Ltd. (1) · Stallergenes Greer (1) · Statens Serum Institut (1) · Xencor, Inc. (1)
United States (8) · Austria (2) · Mexico (2) · Australia (1) · Canada (1) · China (1) · United Kingdom (1)
Abhijit Narvekar, MS, MBBS (1) · Alejandra Sanchez-Rios, MD (1) · Alvaro Borges, MD (1) · Gail Torkildsen, M.D. (1) · Gail Torkildsen, MD (1) · Katrina Pollock, MD (1) · Liang Lu, PhD (1) · Lina S Stoey, MPH (1) · Pernille N Tingskov, BS (1) · Quan D Nguyen, MD, MSc (1) · Rebecca B Dohn, Pharm (1) · Robert Shalwitz, MD (1) · Ronald Goldwater, MD (1)
PMID 19647862, PMID 23181790, PMID 24261946, PMID 34707360, PMID 35585427, PMID 38615673